

### **Surgical Management of Benign Gastric Tumors; Review Article**

#### **Abstract:**

Benign stomach and duodenal tumours are uncommon, accounting for just 5–10% of all stomach tumours and 10–20% of all duodenal tumours. Any component of the stomach epithelium, whether glandular, endocrine, or mesenchymal, can develop benign neoplastic tumours. The majority of people with benign stomach and duodenal tumours are asymptomatic for a long time. When symptoms do appear, they are determined by the tumor's size, location, and comorbidities. Endoscopy, computed tomography, and especially endoscopic ultrasonography results are used to make the diagnosis. Clinically, it's difficult to tell the difference between benign and malignant stomach tumors. Malignant change, severe obstructive problems, and bleeding can occur even in benign tumours. As a result, aggressive steps to surgically resect the tumors should be implemented. Laparoscopic resection has become the first option of many surgeons since the development of minimally invasive surgery. Laparoscopic excision of GIST is safe and effective, according to multiple researches. In this review we'll be looking at Benign Gastric Tumors, Gastrointestinal stromal tumors (GISTs) and their diagnosis, and management.

## **Introduction:**

Benign stomach and duodenal tumours are uncommon, accounting for just 5–10% of all stomach tumours and 10–20% of all duodenal tumours. Although most of these lesions are benign, some of them have the potential to become cancerous. As a result, early detection, adequate treatment, and long-term follow-up are critical. The prevalence of these lesions has increased in recent years as a result of doctors' increased suspicion and the availability and widespread use of diagnostic technologies such as gastrointestinal endoscopy. [1]

Gastrointestinal stromal tumours (GISTs) are an uncommon but unique histologic subclass of mesenchymal-derived intestinal neoplasms. It barely accounts for 0.2 percent of all gastrointestinal cancers. These tumours were previously categorised as leiomyomas, leiomyoblastomas, and leiomyosarcomas because they were thought to develop from smooth muscle. The interstitial cell of Cajal, a pleuro-potential intestinal pacemaker cell, was discovered as the origin of GISTs with the advent of electron microscopy and immunohistochemistry. This cell is located in the myentric plexus, submucosa, and muscularis propria of the gastrointestinal (GI) tract and exhibits myogenic and neurogenic architecture. GISTs are most typically detected in the stomach (40-70%), although they can develop in any portion of the GI tract, with 20 to 40% of GISTs developing in the small intestine and 5 to 15% in the colon and rectum. They develop endophytically, parallel to the gut lumen, and are frequently associated with mucosal necrosis and ulceration. They also come in a variety of sizes, ranging from a few millimetres to 40 centimetres in diameter. A thin pseudocapsule is well characterised in many GISTs. Over 95% of patients have a single primary tumour, and 10 to 40% of these instances have tumours that directly infiltrate surrounding organs. [2-8]

Any component of the stomach epithelium, whether glandular, endocrine, or mesenchymal, can develop benign neoplastic tumours. The stomach epithelium, particularly the mucosa, is made up of a variety of epithelial, neuronal, and endocrine cells organised into glands that perform specific roles. Any of these cells has the potential to become cancerous. Only around 5% of stomach tumours are benign. The majority of benign stomach tumours are asymptomatic and discovered during exams for unrelated symptoms. Anemia from prolonged occult

bleeding is the most common presenting symptom. Epigastric discomfort or acute GI bleeding from tumour ulceration are less prevalent. [9]

GI bleeding and abdominal discomfort are common symptoms of gastric GISTs. The majority of patients, on the other hand, are asymptomatic, and the lesions are identified by chance during an upper endoscopy conducted for another cause. Due to the lack of evident clinical or pathological indicators of malignancy other than visible metastasis during surgery, their metastatic potential is difficult to predict. Furthermore, local recurrence or distant metastases might take years to manifest after the original diagnosis. Gastric GISTs must be surgically resected to be cured. In the past, it was assumed that a 1 to 2 cm margin was required for a satisfactory resection. DeMatteo et al. has established that survival is determined by tumour size rather than negative microscopic surgical margins. These findings support GISTs lesions being resected locally, including wedge and gastric resections. [2,10-13]

### **Demographic Data:**

In most studies, the reported incidence of GISTs is 1–2 instances per 100,000 persons per year. GISTs are diagnosed at a median age of 60–65 years, with a male to female gender ratio of about 1:1. Sreide et al. found symptomatic illness in 81.3 percent of patients with GISTs and incidental asymptomatic disease in 18.7% of patients in a systematic review of 15 studies including 2,456 patients with GISTs. Abdominal discomfort was the most prevalent symptom in 61 percent of GIST patients, followed by gastrointestinal bleeding such as hematemesis or melena in 58 percent, and an intestinal obstruction or palpable mass in a smaller percentage of cases. [14-16]

GISTs are most commonly detected in the stomach (55.6 percent), small bowel (31.8 percent), and less frequently in the colon and rectum (6 percent), other diverse places (5.5 percent), and the oesophagus (0.7 percent) (7). The mesentery, omentum, and retroperitoneum are all places where extra-gastrointestinal GISTs can be detected. Coe et al. used the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database to look at the mortality rates of GISTs of less than 2 cm and found that patients with regional advanced GISTs (34%) or metastatic GISTs (34.3%) had significantly higher 5-year GIST-specific mortality than those with localised GISTs (5.6 percent

). Due of their persistent malignant potential danger, it is consequently difficult to describe any GISTs as "benign" at this time, particularly those with modest diameters. [14,17,18]

### **Diagnosis:**

The majority of people with benign stomach and duodenal tumours are asymptomatic for a long time. When symptoms do appear, they are determined by the tumor's size, location, and comorbidities (eg: bleeding and ulceration). The most common presenting symptoms are bleeding (acute or chronic), abdominal pain, nausea, weight loss, intestinal obstruction, and recurrent pancreaticobiliary side effects such as jaundice, cholangitis, and pancreatitis in periampullary tumours such as adenomas in the papilla of Vater. [1]

Endoscopy, computed tomography, and especially endoscopic ultrasonography results are used to make the diagnosis. It is the only approach that can accurately determine the tumor's intramural nature, with a diagnostic accuracy of 92 percent. The tumor's specific location in various layers may indicate the histological type, but the complete tumour must be inspected to provide a definitive diagnosis. Surgery is required for symptomatic tumours, however the role of surgery in asymptomatic tumours (particularly tiny tumours) is still debatable. Despite high morbidity, laparotomy was the chosen treatment until recently. However, the advent of minimally invasive surgery has sparked various investigations on laparoscopic excision of submucosal stomach cancers. Only a few cases have been recorded in the literature, and only two series with more than 30 individuals have been published to far. [9,19-22]

Spiral CT Scan and Electro Beam CT Scan with 3-D reconstruction are two new high-tech imaging techniques that may be employed for diagnosis right now. Polyps (epithelial tumours) are the most frequent benign lesions in the stomach, accounting for 75 percent of all benign stomach tumours. Leiomyomas are another type of benign stomach tumour. Adenoma, including Brunner's gland adenomas, is the most prevalent benign lesion in the duodenum, followed by leiomyomas and lipomas. [1]

### **Management:**

Clinically, it's difficult to tell the difference between benign and malignant stomach tumours. Malignant change, severe obstructive problems, and bleeding can occur even in benign tumours. As a result, aggressive steps to surgically resect the tumours should be implemented. Surgical resection should be conducted if the nature of the tumour is still unknown. It's still up in the air as to whether surgical procedure is best. Only cancers affecting the stomach orifices, tumours measuring 5 cm or larger, and tumours with a broad implantation base that prevent wedge resection are candidates for gastrectomy. [9]

Every GIST is now considered to be cancerous. Most recommendations strongly advise resecting a stomach submucosal tumour if it cannot be identified with high certainty, especially if it is larger than 2 cm (although Eckardt's editorial supported 3 cm as a reason for surgery). Because of the low risk of malignancy, smaller tumours may be noticed; nonetheless, patients should be advised of the risk of malignancy regardless of tumour size. Small GISTs smaller than 2 cm should be surgically removed if they have high-risk EUS symptoms such as an uneven border, cystic gaps, ulceration, echogenic foci, or heterogeneity, according to NCCN recommendations. However, as previously stated, there is no agreement on the criterion for doing EUS for GISTs less than 2 cm on endoscopy. [23]

In terms of resection depth, the general trend is to remove the whole stomach wall layer. Several laparoscopic techniques for benign stomach tumours have been published in the literature. A totally laparoscopic approach (wedge resection, intragastric resection, transgastric endoluminal resection, distal gastrectomy, and gastrojejunostomy) and a coupled laparoscopic-endoscopic approach (Endo-organ intragastric resection, DEILO), transgastric tumor-everting excision, and enucleation) are the two options. [9,24-28]

When the tumour is very big and there is a risk of rupture, haemorrhage, or substantial combined resection, imatinib can be used as a neoadjuvant therapy. With the National Comprehensive Cancer Network (NCCN) and ESMO standards, the surgeon's discretion is crucial when choosing on neoadjuvant therapy. Pathologic confirmation by endoscopy, EUS, or percutaneous access is required when neoadjuvant imatinib is chosen. Because of the unproven risk of peritoneal dispersion, percutaneous entry is usually the last resort. Mutational analysis should be used whenever feasible to establish a baseline mutation and the

existence of the PDGFRA D842V mutation, which is known to be resistant to imatinib. [23]

Resection of certain tumours is more challenging due to their location. The entire top section of the stomach may have to be mobilised if the tumour is in or near the fundus. If the tumour is located posteriorly, after opening the omental bursa, a posterior approach to the tumour may be necessary. Otherwise, an anterior gastrotomy can be used to get access. To minimise constriction of the gastric lumen, tumours near the cardia or pylorus must be excised with as little good tissue as necessary. Because the lesions cannot be palpated, small stomach leiomyomas can be removed completely laparoscopically with the use of intraoperative laparoscopic ultrasonography. For pylorus tumours, a laparoscopic distal gastrectomy with gastrojejunostomy is performed. Direct viewing enables for accurate localisation of the lesion using a combination laparoscopic-endoscopic technique. According to published statistics, laparoscopic excision of benign stomach cancers is a reliable and safe procedure. The conversion rate has fluctuated between 0% and 22%. The operation takes about the same amount of time as a laparotomy, and there are benefits such as reduced postoperative discomfort, earlier oral feeding, and a shorter hospital stay. In our patients, the average postoperative hospital stay was 5 days (range, 4 to 6), which is consistent with many other studies. The usage of drains on a regular basis might be linked to paranoia and is most likely unnecessary. [9,29,30]

Despite the fact that complete surgical removal of tumours offers the highest chance of cure, the high rates of metastasis and recurrence in GISTs with a high malignant potential underline the need for effective non-surgical therapies. Patients with unresectable or metastasized malignant GISTs had no active therapy options prior to the introduction of imatinib mesylate. It prevents the growth factor receptor c-KIT from transmitting signals, which limits cell proliferation and metabolism. As a result, it may help patients with incompletely resected, metastatic, or recurrent gastric GIST improve their clinical results. [2]

**Laparoscopic Technique Based on Tumor Location:** Trocar placement varies depending on the tumours' and operators' positions, but it's not dissimilar to the places utilised in laparoscopic procedures for early gastric cancer or Nissen fundoplication. Depending on the patient's wishes, the operator can stand

between the patient's legs or on the right side of the patient. The position of the trocar for the linear stapler and the needle holder should be chosen with the stapling or suturing direction in mind. Staplers may be inserted from the left side to create a stapler line perpendicular to the long axis of the stomach to avoid stenosis, and the use of rotating staplers may give further assistance. When a lesion is found in the upper stomach, the trocars are moved to the left and proximally, and when a lesion is found in the lower stomach, the trocars are moved distally. Depending on the situation, one or two assistants' trocars and an epigastric trocar for liver retraction can be introduced. During the laparoscopic technique, intra-operative endoscopy or laparoscopic ultrasonography may be utilised to find tiny lesions or help in excision. [23]

**Recurrences:** In a published series, the recurrence rate following surgery varied from 17 percent to 24 percent. The recurrence rate in a study was 8.5 percent, with a median time of 14.3 months (range, 7 to 28 months). Three individuals reported in that study with recurrence all had tumours larger than 10 cm, suggesting that tumours larger than 10 cm are more likely to return. In comparison to the literature, that study had a higher five-year survival rate of 84 percent (45 percent to 76 percent). The lower percentage of patients with tumours larger than 10cm (20%) and the philosophy of careful surgical method to which it was adhered to may have contributed to these improved patient outcomes. Another possibility is that just one patient experienced tumour rupture during surgery, which has previously been linked to early recurrence and poor prognosis. The hypothesis that by the time a tumour grows to a significant size, it becomes more predisposed to peritoneal seeding by spreading out of the tumour via higher intratumor pressure or loosened tumour cellular adhesion, whereas smaller tumours are more likely to remain intact in the submucosal layer may account for the predominant recurrence pattern of peritoneal seeding and the higher recurrence risk in patients with large tumors. [2]

From 2001 to 2003, the American College of Surgeons Oncology Group performed research that looked at the long-term outcomes of 106 patients with high-risk GISTs who had total gross GISTs resection followed by adjuvant imatinib at 400 mg/d for a year. The 1-, 3-, and 5-year OS rates were 99 percent, 97 percent, and 83 percent, respectively, after a median follow-up of 7.7 years. The RFS rates after one, three, and five years were 96 percent, 60 percent, and 40 percent,

respectively. Lower RFS rates were linked to bigger tumour size, KIT exon 9 mutation, high mitotic rate, and older age, whereas lower OS rates were linked to older age and a high mitotic rate. [14]

### **Conclusion:**

Laparoscopic resection has become the first option of many surgeons since the development of minimally invasive surgery. Laparoscopic excision of GIST is safe and effective, according to multiple researches. While patient characteristics (older age and male gender) and tumour factors (size and mitotic index) might help predict prognosis, surgeons must focus on surgical factors (incomplete resection margin, tumour rupture, or spillage) when choosing surgical resection approaches. All of these parameters have an impact on the final oncological outcome, including RFS and OS. However, when compared to the open procedure, laparoscopic procedure has equivalent Tumor size, operating duration, and predicted blood loss, while having statistically shorter hospital stay.

### **References:**

1. Goh PMY, Lenzi JE. Benign tumors of the duodenum and stomach. In: Holzheimer RG, Mannick JA, editors. Surgical Treatment: Evidence-Based and Problem-Oriented. Munich: Zuckschwerdt; 2001. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK6948/>
2. El-Hanafy E, El-Hemaly M, Hamdy E, El-Raouf AA, El-Hak NG, Atif E. Surgical management of gastric gastrointestinal stromal tumor: a single center experience. Saudi J Gastroenterol. 2011 May-Jun;17(3):189-93. doi: 10.4103/1319-3767.80382. PMID: 21546722; PMCID: PMC3122089.
3. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.

4. Nowain A, Bhakta H, Pais S, Kanel G, Verma S. Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis. *J Gastroenterol Hepatol.* 2005;20:818–24.
5. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumors. *J Clin Pathol.* 2001;54:96–102.
6. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. *Hum Pathol.* 2002;33:459–65.
7. Mignon F, Julié C, Izzillo R, Luciani A, Guichoux F, Mesurolle B, et al. Imaging features of gastric stromal tumors: Radiologic-pathologic correlation. Report of 4 cases. *J Radiol.* 2000;81:874–81.
8. Loong HH. Gastrointestinal stromal tumors: A review of current management options. *Hong Kong Med J.* 2007;13:61–5.
9. Palanivelu C, Rangarajan M, Parthasarathi R, Senthilkumar R. Laparoscopic resection for benign tumors of the stomach. *JSLs.* 2007 Jan-Mar;11(1):81-6. PMID: 17651562; PMCID: PMC3015806.
10. Matthews BD, Walsh RM, Kercher KW, Sing RF, Pratt BL, Answini GA, et al. Laparoscopic vs open resection of gastric stromal tumors. *Surg Endosc.* 2002;16:803–7.
11. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol.* 2005;29:52–68.
12. Cuschieri A. Laparoscopic gastric resection. *Surg Clin North Am.* 2000;80:1269–84.
13. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. *Ann Surg.* 2000;231:51–8.
14. Lim KT. Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective. *Transl Gastroenterol Hepatol.* 2017 Dec 7;2:104. doi: 10.21037/tgh.2017.12.01. PMID: 29354761; PMCID: PMC5762995.
15. Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-

- based cohort studies. *Cancer Epidemiol* 2016;40:39-46.  
10.1016/j.canep.2015.10.031
16. Caterino S, Lorenzon L, Petrucciani N, et al. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. *World J Surg Oncol* 2011;9:13. 10.1186/1477-7819-9-13
  17. Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. *Radiographics* 2003;23:283-304, 456; quiz 532.
  18. Coe TM, Fero KE, Fanta PT, et al. Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. *J Gastrointest Surg* 2016;20:1132-40. 10.1007/s11605-016-3134-y
  19. Choi YB, Oh ST. Laparoscopy in the management of gastric submucosal tumors. *Surg Endosc*. 2000;14:741–745
  20. Otani Y, Ohgami M, Igarashi N, et al. Laparoscopic wedge resection of gastric submucosal tumors. *Surg Laparosc Endosc Percutan Tech*. 2000;10:19
  21. Gurbuz AT, Peetz ME. Resection of a gastric leiomyoma using combined laparoscopic and gastroscopic approach. *Surg Endosc*. 1997;11:285–286
  22. Rothlin M, Schob O. Laparoscopic wedge resection for benign gastric tumors. *Surg Endosc*. 2001;15:893–895
  23. Kong SH, Yang HK. Surgical treatment of gastric gastrointestinal stromal tumor. *J Gastric Cancer*. 2013 Mar;13(1):3-18. doi: 10.5230/jgc.2013.13.1.3. Epub 2013 Mar 31. PMID: 23610714; PMCID: PMC3627804
  24. Hiroyuki K, Erito M, Takayuki A, Hiroyuki K, Tatsuo S, Souichi T. Double endoscopic intraluminal operation for upper digestive tract diseases: Proposal of a novel procedure. *Ann Surg*. 2004;239(1):22
  25. Pereira SG, Davies RJ, Ballantyne GH, Duperier T. Laparoscopic wedge resection of a gastric leiomyoma. *Surg Endosc*. 2001;15(8):896–897
  26. Gamal EM, Altorjay A, Szanto I, Garcia J, Kiss J. Laparoscopic wedge resection of the gastric wall for gastric benign tumor. The collaboration of the laparoscopic surgeon and the endoscopist. *Acta Chir Hung*. 1999;38(2):167–168
  27. Walsh RM, Heniford BT. Laparoendoscopic treatment of gastric stromal tumors. *Semin Laparosc Surg*. 2001;8:189–194

28. Basso N, Rosato P, De Leo A, et al. Laparoscopic treatment of gastric stromal tumors. Surg Endosc. 2000;14:524–526
29. Lliorente J. Laparoscopic gastric resection for gastric leiomyoma. Surg Endosc. 1994;8:887–889
30. Ashish Rohatgi A, Singh KK. Laparoendoscopic management of gastrointestinal stromal tumors. J Laparoendosc Adv Surg Tech. 2003;13(1):37–40-13

UNDR PEER REVIEW